Pulse Biosciences
PLSE
45.55
+1.14
+2.57%
Pulse Biosciences
US · PLSE
#2388 by market cap
Listed 2016
45.55
+1.14
+2.57%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Mizuho Securities Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Raises Target Price to $45Market Newswire · 2026/8/10
-
Rating change
Needham Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $58Market Newswire · 2026/8/17
-
Rating change
BTIG Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $70Market Newswire · 2026/9/23
-
Rating change
CCORF Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Maintains Target Price $58Market Newswire · 2026/10/8
-
Rating change
Mizuho Securities Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Raises Target Price to $55Market Newswire · 2026/10/13
-
Rating change
Freedom Capital Markets Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $73Market Newswire · 2026/9/9
-
Rating change
CCORF Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Maintains Target Price $43Market Newswire · 2026/8/12
-
Rating change
Mizuho Securities Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/4/13
-
Rating change
Oppenheimer Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Raises Target Price to $35Market Newswire · 2026/7/28
-
Rating change
Analysts Offer Insights on Healthcare Companies: Pulse Biosciences (PLSE), OmniAb (OABI) and Halozyme (HALO)TipRanks · 2026/10/7
-
Mizuho Securities Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Raises Target Price to $65Market Newswire · 2026/11/6
-
Rating change
Canaccord Genuity Keeps Their Buy Rating on Pulse Biosciences (PLSE)TipRanks · 2026/7/30
-
CCORF Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Raises Target Price to $74Market Newswire · 2026/11/6
-
Rating change
CCORF Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $32Market Newswire · 2026/6/4
-
Rating change
Oppenheimer Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Raises Target Price to $60Market Newswire · 2026/10/13
-
BTIG Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/11/6
-
Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q3 Revenue $400,000, Vs. FactSet Est of $521,000MT Newswires · 2026/11/6
-
Rating change
CCORF Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Raises Target Price to $58Market Newswire · 2026/10/6
-
Earnings Preview: PLSE to Report Financial Results Post-market on November 05Market Newswire · 2026/10/31
-
Rating change
CCORF Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Raises Target Price to $43Market Newswire · 2026/8/10
-
Rating change
Oppenheimer Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $22Market Newswire · 2025/7/8
-
Rating change
Oppenheimer Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Maintains Target Price $22Market Newswire · 2025/11/6
-
Rating change
Mizuho Securities Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $25Market Newswire · 2026/1/30
-
Rating change
Mizuho Securities Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Raises Target Price to $30Market Newswire · 2026/2/6
-
BTIG Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/10/7
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Pulse Biosciences discussion 0 comments